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It is often assumed that the assessment by the SMC influences subsequent local 
recommendations on the funding and use of medicines in England. This research 
tests that hypothesis. Methods: Research was based on 86 medicines assessed 
by the SMC in 2012 and 2013, of which 56 were not reviewed by NICE. A sample of 
five local assessment groups in England was identified. From these we found a total 
of 53 recommendations relating to medicines not reviewed by NICE, of which 27 
were published subsequent to the SMC assessment. Results: Only around half 
(51%) of local assessments in England were published subsequent to SMC assess-
ments, so could potentially have been influenced. Of these recommendations 
two-thirds (18) were consistent with the SMC verdict, and one third (9) differed. 
Detailed analysis revealed additional factors. Several of the medicines in the sam-
ple were recommended by NICE on the basis of evidence summaries or in clinical 
guidelines. This advice, although not mandatory, appears from our sample to have 
been followed. Also some medicines not recommended by SMC were subject to 
specialised commissioning, the responsibility of NHS England rather than local 
commissioners. ConClusions: There is some consistency between assessments 
of new medicines in Scotland and England (as might be expected given that the 
evidence and decision criteria are broadly similar) but there are also significant dif-
ferences. It appears English advisory bodies make their decisions independently of 
SMC recommendations, and often earlier. Other differences, such as NICE evidence 
summaries and Specialised Commissioning in England, further reduce the influ-
ence of Scottish decisions.
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objeCtives: The framework specifications on pharmaceuticals (Rahmenvorgaben 
Arzneimittel) by the National Association of Statutory Health Insurance-Accredited 
Physicians (KBV) and the Statutory Health Insurance Scheme (GKV-Spitzenverband) 
are annually redefined. These specifications (Rahmenvorgaben) are binding for 
the 17 subnational drug agreements (Arzneimittelvereinbarungen) and target 
agreements (Zielvereinbarungen). They include quotas for lead compounds and 
prescription quotas. Individual subnational districts (KV Gebiete) set local drug 
specifications and quotas. These guide the prescription behavior. The objective of 
the analysis is to identify differences between the subnational regions regarding 
target agreements and resulting impacts. The analysis focuses also on the shift from 
innovative biologics to biosimilar products. Methods: The 17 subnational drug 
target agreements (Zielvereinbarungen) are analyzed regarding their differences/ 
specialities and their regulatory effect on the prescription of pharmaceutical classes 
e.g. anti-diabetic, anti-hypertensives, and the biosimilar proportion. Additionally 
the rapid prescription information of the SHI (GKV-Arzneimittel-Schnellinformation 
= GAmSi-data) and local regulation instruments are reviewed. Results: The 17 tar-
get agreements (Zielvereinbarungen) for the 15 defined classes of pharmaceuticals 
result in different quota fulfillment. An example is erythropoetin with a quantita-
tive quota range from 20% to 63%. The qualitative regulatory actions regarding the 
switch of biologics (Erythropoetin, Somatropin, Filgrastim, TNF alpha-blocker) to 
biosimilars vary from no regulation to recommendation or even priority prescrip-
tion. The additional defined subnational target agreements (Zielvereinbarungen) 
include targets on diabetes test strips, biosimilar quotas, individual substances or 
product-classes and can be individually adapted for the different physician spe-
cialties. ConClusions: In addition to the federal regulation system the German 
pharmaceutical market is fragmented in 17 subnational areas leading to different 
treatment behavior depending on the relevant subnational target agreements and 
the defined quotas. This analysis shows the wide variety of the subnational target 
agreements for different drug classes. They are not uniform and on a qualitative 
basis they even can exceed the determined federal targets.
PHP193
a systematic comPaRision of iqwig RecommenDations anD g-Ba 
Decisions in tHe amnog PRocess in geRmany
Vollmer L1, Dröschel D1, Fröhlich N2, de Paz B3, Walzer S1
1MArS Market Access & Pricing Strategy GmbH, Weil am Rhein, Germany, 2NF, Bremen, Germany, 
3PRIORITIS Market Access, Paris, France
objeCtives: Since the introduction of AMNOG more than 100 IQWiG recommenda-
tions and G-BA decisions on the early benefit assessment have been published. In 
various assessments, the IQWiG recommendation and the related G-BA decision differ 
in terms of argumentation and result. In this study, these differences were systemati-
cally analyzed in order to draw conclusions for further proceedings. Methods: Data 
of all published IQWiG recommendations and G-BA decisions were standardized and 
transferred into the Prismaccess database. In a systematic analysis, major differ-
ences between the recommendations and decisions were quantitatively assessed. 
All documents of the identified decisions where differences were observed were 
then compared qualitatively. Results: In several aspects, major differences were 
found between IQWiG recommendations and G-BA decisions in approximately 25% 
of all cases. On the subgroup level, it was observed in at least n= 10 cases that the 
G-BA tends to use a broader definition of subgroups in its decisions than used in the 
IQWiG dossiers, (e.g. Telaprevir). In terms of the extent of the additional benefit, 17 
differences between IQWiG and G-BA decisions were registered, while mostly G-BA 
tend to evaluate better than IQWiG. In the probability of the additional benefit also 
some differences were observed. This can be explained by the opportunity to provide 
additional/new evidence during the oral hearing, which may influence the decision 
positively. Some proceedings were identified that took another way, as intended by 
the legislature: for example with Cobicistat, an incomplete paperwork was handed 
in, to achieve at least the price of the ACT. Still accepted by the G-BA, it is obvious 
that this should not be the normal case. ConClusions: In an early stage, G-BA 
consultations might be helpful clarifying subgroups-requirements. In the process, 
the oral hearing was identified as important instrument to supplement the required 
data and to correct uncertain issues from the dossier.
rules to calculate the price of branded drugs. Typically there is no negotiation 
between manufacturers and the IPR body. In the context of the German AMNOG 
price negotiations and the role of Germany as a key reference country, there is 
dearth of evidence on the international impact of the AMNOG law. Our objective 
was to evaluate the potential impact. Methods: An IRP tool (Orange) was used 
to simulate scenarios of price agreements for a new branded drug between the 
German Head Association of the Statutory Health Insurance Companies and the 
manufacturer. The impact of the price agreement on other countries was evalu-
ated based on the existing IRP rules as defined in the Orange tool. All prices were 
initially set at 100 euro to limit the impact to Germany only. Results: A 50% 
price drop in Germany, for example, would lead to a range of reductions across 
the world. The largest impact in Europe would be in France, Romania, Russia, 
Slovenia and Luxembourg (50% decrease) followed by Norway, Greece (17%) and 
the Netherlands (13%). Switzerland, Ireland, Denmark and Austria would be only 
marginally impacted. In contrast, with a price increase in Germany of 25% a limited 
impact in other countries was observed. Such an increase would lead to 6% price 
rise in the Netherlands, 4% in Switzerland, 3% in Ireland and Denmark, and a 1% 
increase in Austria. ConClusions: Price negotiations in Germany could poten-
tially impact the price of new branded therapies in numerous other countries. 
Ongoing downward pressure on pharmaceutical prices could ultimately have a 
negative impact on innovation and drug development in Europe.
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objeCtives: Both ultra orphan and cancer drugs are premium priced therapies 
with high annual per patient costs. The local legislation and reimbursement 
mechanisms have had significant impact on pricing trends for these therapies. 
The objectives of this analysis were to compare the price differential for ultra 
orphan and cancer drugs in the US and the UK, and understand the impact of 
local reimbursement mechanisms. Methods: A set of 22 drugs (10 ultra orphan 
and 12 cancer drugs) was selected based on their availability in the US and the UK. 
The 2014 AWP, WAC and net prices were obtained for all 22 drugs. All UK prices 
were converted to USD. Primary discussions with ex-payer and policy experts 
were conducted to understand the basis and implication of the price differen-
tials. Results: For ten selected ultra orphan drugs, the median WAC price pre-
mium for the US compared to the UK net price was 10%. For 12 selected cancer 
drugs the median WAC price premium for the US compared to the UK net price 
was 106% (based on AWP the premiums were 29% and 149%, respectively). Eight 
out of 10 ultra orphan and 12 out of 12 cancer drugs were higher priced in the US 
compared to the UK. Primary discussions with experts suggest the role of legisla-
tion for coverage of cancer drugs in the US and special coverage of rare disease 
products in the UK and reimbursement mechanisms (use of cost effectiveness 
driven HTAs in the UK and the use of co-pay in the US) as primary drivers of high 
price differential for cancer drugs versus ultra orphan therapies. ConClusions: 
The local reimbursement mechanisms are major drivers of price differential for 
ultra orphan and cancer drugs in the US and the UK.
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objeCtives: Pharmaceutical industry continues to grow and drug prices are a bur-
den for countries. Reference price system is assumed that such a practice concern-
ing medicines will lead to a decrease in medicine expenditures as medicine prices 
decrease. The objectives of this analysis to determine the distribution of discount 
of original medicines which has no generics from the reimbursement agency per-
spective in Turkey. Methods: In the analysis,“Detailed Price List” data published 
on the website of the Ministry of Health’s Turkish Medicines and Medical Devices 
Agency(TMMDA) and “Annex 4-A Funded Medicines List” data published by Social 
Security Institution(SSI) were used. The lists were merged using the Excel software 
and generic medicine including genericized original medicines with different pric-
ing and payment conditions compared to original medicines with no generics and 
other specific medicines such as blood products,enteral nutrition products, etc. and 
specific conditions such as medicines with no reimbursement were excluded. The 
analysis was made with a total of 568 original medicines with no generic. Ex-factory 
prices were used in the analysis. The reference prices of all original medicines 
(100%)are calculated by multiplying their actual reference price values with the 
periodic Euro value in the price list used in Turkey. Results: A comparison between 
ex-factory prices in TL and actual reference prices in TL revealed that 42.6% of the 
medicines had the same price,while 57.4% had a different price.The distribution of 
discount rates applied by SSI for 370 original medicines with a 41% discount rate 
and 99 original medicines with a 32.5% discount rate were found. ConClusions: 
In this analysis the mandatory discount rate for original drugs of 41% discount 
is mostly implemented by SSI. In rare cases, higher or lower discount rate can be 
applied. This is compatible with the implementation of the original drug reimburse-
ment policy rules. However, further analysis should be done to obtaining more 
detailed information.
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objeCtives: The Scottish Medicines Consortium (SMC), unlike the National 
Institute for Health and Care Excellence in England, assesses all new medicines. 
